ALTANA Pharma AG (AAA): Once-Daily Alvesco Provides Comparable Relief Of Asthma Symptoms To Twice-Daily Budesonide And Fluticasone
10/19/2005 5:13:04 PM
BAD HOMBURG, Germany--(BUSINESS WIRE)--March 21, 2005--ALTANA Pharma, the pharmaceutical group of ALTANA AG (NYSE:AAA; FWB:ALT), presented data during the American Academy of Allergy, Asthma and Immunology's (AAAAI) 61st annual meeting, demonstrating that once-daily Alvesco(R) (ciclesonide), a new inhaled corticosteroid for the treatment of asthma, is comparable to already marketed twice-daily inhaled corticosteroids, budesonide and fluticasone propionate.
"Often, patients will miss a dose of their asthma medication, which could increase the likelihood of serious asthma complications," noted principal investigator Professor H. Magnussen, Medical Director of the Centre of Pneumology and Thoracic Surgery in Grosshansdorf, Germany. "These findings are significant because they show that patients can control their symptoms with a once-daily inhalation like Alvesco, which may enhance compliance."